These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37088527)

  • 21. A
    Shoaf SE; Ouyang J; Sergeyeva O; Estilo A; Li H; Leung D
    Clin J Am Soc Nephrol; 2020 May; 15(5):643-650. PubMed ID: 32241780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.
    Wang X; Constans MM; Chebib FT; Torres VE; Pellegrini L
    Am J Nephrol; 2019; 49(6):487-493. PubMed ID: 31117065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
    Xie X; Cai Q; Guo XY; Bai DH; Sheng HZ; Wang BK; Yan K; Lu AM; Wang XR
    Comb Chem High Throughput Screen; 2020; 23(1):6-16. PubMed ID: 31793415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycystic Kidney Disease and the Vasopressin Pathway.
    van Gastel MDA; Torres VE
    Ann Nutr Metab; 2017; 70 Suppl 1():43-50. PubMed ID: 28614813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzodiazepine Derivatives as Potent Vasopressin V
    Cao X; Wang P; Yuan H; Zhang H; He Y; Fu K; Fang Q; Liu H; Su L; Yin L; Xu P; Xie Y; Xiong X; Wang J; Zhu X; Guo D
    J Med Chem; 2022 Jul; 65(13):9295-9311. PubMed ID: 35579344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?
    Mustafa RA; Yu ASL
    Clin J Am Soc Nephrol; 2018 Jul; 13(7):1107-1109. PubMed ID: 29653956
    [No Abstract]   [Full Text] [Related]  

  • 27. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.
    Uchiyama K; Kitayama C; Yanai A; Ishibashi Y
    Sci Rep; 2021 Sep; 11(1):17666. PubMed ID: 34480075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
    Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.
    Rinschen MM; Schermer B; Benzing T
    J Am Soc Nephrol; 2014 Jun; 25(6):1140-7. PubMed ID: 24556353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Practical approach to patient therapy affected by Autosomal Dominant Autosomic Polycystic Kidney Disease].
    Esposito C; La Milia V; Altobelli C; Cerutti R; Manunta P; Dallera N; Piscopo G; Magistroni R
    G Ital Nefrol; 2018 Jul; 35(4):. PubMed ID: 30035441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
    Devuyst O; Chapman AB; Gansevoort RT; Higashihara E; Perrone RD; Torres VE; Blais JD; Zhou W; Ouyang J; Czerwiec FS
    J Am Soc Nephrol; 2017 May; 28(5):1592-1602. PubMed ID: 27920153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment.
    Lee Y; Blount KL; Dai F; Thompson S; Scher JK; Bitterman S; Droher M; Herzog EL; Moeckel G; Karihaloo A; Dahl NK
    Clin Exp Nephrol; 2018 Aug; 22(4):906-916. PubMed ID: 29453607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
    Chebib FT; Perrone RD; Chapman AB; Dahl NK; Harris PC; Mrug M; Mustafa RA; Rastogi A; Watnick T; Yu ASL; Torres VE
    J Am Soc Nephrol; 2018 Oct; 29(10):2458-2470. PubMed ID: 30228150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K; Fox A; Gilbert R
    Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature.
    Capuano I; Buonanno P; Riccio E; Rizzo M; Pisani A
    Clin Nephrol; 2022 Mar; 97(3):131-140. PubMed ID: 34846296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease.
    Ackley W; Dahl NK; Park M
    Adv Kidney Dis Health; 2023 May; 30(3):228-235. PubMed ID: 37088525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyponatremia and cyst growth in neonatal polycystic kidney disease: a case for aquaretics?
    Bockenhauer D
    Pediatr Nephrol; 2017 May; 32(5):721-723. PubMed ID: 28194573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
    Kramers BJ; Koorevaar IW; van Gastel MDA; van Goor H; Hallows KR; Heerspink HL; Li H; Leonhard WN; Peters DJM; Qiu J; Touw DJ; Gansevoort RT; Meijer E
    Clin J Am Soc Nephrol; 2022 Apr; 17(4):507-517. PubMed ID: 35314480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment.
    Minatoguchi S; Hayashi H; Umeda R; Koide S; Hasegawa M; Tsuboi N
    CEN Case Rep; 2024 Oct; 13(5):419-424. PubMed ID: 38494546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.